https://european-biotechnology.net/wp-content/uploads/2026/04/biontech-trastuzumab-pamirtecan-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-11 15:18:292026-04-11 15:18:29BioNTech reports promising Phase II data for uterine cancer ADC
https://european-biotechnology.net/wp-content/uploads/2026/04/immo-wegmann-DgRNOR1z0s4-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-08 09:42:082026-04-08 09:42:08Jeito Capital raises record US$1.2bn to bankroll European biopharma’s next generation
https://european-biotechnology.net/wp-content/uploads/2026/04/EB.com_Flagge_Portugal_kl-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-06 05:00:162026-04-06 05:00:16Portugal’s biotech industry is growing up
https://european-biotechnology.net/wp-content/uploads/2026/04/generare-ai-team-paris-web.png541960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-02 06:01:332026-04-02 06:01:33French AI: 20 million funding for Generare to find better data in nature
https://european-biotechnology.net/wp-content/uploads/2026/04/getty-images-7G9O2iyJZ_k-unsplash-1030x688-1.jpg6881030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-01 08:00:392026-04-01 08:00:39Lilly moves deeper into sleep medicine with up to $7.8 billion Centessa deal
https://european-biotechnology.net/wp-content/uploads/2026/03/Novatis.jpg450940Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-03-30 07:58:252026-03-30 07:58:25Something of a shopping spree: Novartis to acquire US-based Excellergy for up to $2bn
